Abstract:Introduction: Vascular stiffness increases with age and independently predicts cardiovascular events but vascular fibrosis mechanisms are unclear. Epigenetic changes accumulate with age and contribute to aging pathology. We showed that aging-associated increase in vascular stiffness/fibrosis are mitigated by treating old mice with mineralocorticoid receptor (MR) antagonist (MRA) or by genetic deletion of MR in smooth muscle cells (SMC-MR-KO). Hypothesis: We hypothesized that SMC-MR regulates vascular fibrosis genes by modulating epigenetic histone modifications in the aging vasculature. Methods and Results: Global histone proteomic profiling revealed increased acetylation (ac) and decreased methylation (me) of histone H3 lysine 27 (H3K27) in old vs young mouse aorta that is attenuated by SMC-MR-KO. Similarly, RNA profiling shows downregulation of fibrotic genes (CTGF, MMP2 and Integrin-α5) with aging in mouse aortas from SMC-MR-KO mice. Mechanism was explored in primary low passage human aortic SMC (HASMC). Comparison of protein levels in HASMCs from old vs young people shows increased MR, decreased H3K27-specific methyltransferase EZH2, increased H3K27ac and increased fibrosis gene expression in aged HASMC. Treatment of young HASMC with H 2 O 2 (aging inductor) increased MR and decreased EZH2 in association with decreased H3K27me. These epigenetic changes were associated with increased H3K27ac and MR enrichment at the promoter of fibrosis genes by ChIP along with increased fibrosis gene expression. Conversely, treatment of aged HASMC with MRA increased EZH2 and H3K27me with decreased fibrosis gene expression. Finally, treatment of 12 month old mice with MR antagonist for 4 months or deletion of MR from SMC prevented aging induction of vascular stiffness by pulse wave velocity in association with decreased H3K27ac at promoters and decreased expression of fibrosis genes in aging aortas. Conclusion: These data support a model in which rising SMC-MR with aging contributes to vascular fibrosis via EZH2 reduction leading to decreased H3K27me and increased H3K27ac and MR recruitment to promote transcription of fibrotic genes. These findings suggest the therapeutic potential for MRAs for aging-associated vascular stiffening/fibrosis.

Aryl hydrocarbon receptor: From pathogenesis to therapeutic targets in aging-related tissue fibrosis

Aryl hydrocarbon receptor: Linking environment to aging process in elderly patients with asthma

CC chemokines family in fibrosis and aging: From mechanisms to therapy

The Aryl Hydrocarbon Receptor, Epigenetics and the Aging Process

The potential role of senescence in limiting fibrosis caused by aging

Targeting SIRT2 in Aging-Associated Fibrosis Pathophysiology

The NLRP3 inflammasome in fibrosis and aging: The known unknowns

CX3C chemokine: Hallmarks of fibrosis and ageing

The aryl hydrocarbon receptor promotes aging phenotypes across species

Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues

Unraveling the hepatic stellate cells mediated mechanisms in aging's influence on liver fibrosis

Progress in Cellular Senescence and Organ Fibrosis

Aging Reprograms the Hematopoietic-Vascular Niche to Impede Regeneration and Promote Fibrosis

The role of inflammatory and fibrogenic pathways in heart failure associated with aging

Deciphering the role of lipoproteins and lipid metabolic alterations in ageing and ageing-associated renal fibrosis

Aryl hydrocarbon receptor (AhR) reveals evidence of antagonistic pleiotropy in the regulation of the aging process

CXCL12/CXCR4: an amazing challenge and opportunity in the fight against fibrosis

Aryl Hydrocarbon Receptor Pathway: Role, Regulation and Intervention in Atherosclerosis Therapy

CircRNAs: Decrypting the novel targets of fibrosis and aging

Arachidonic acid in aging: New roles for old players

Abstract 8929: Mineralocorticoid Receptor As an Epigenetic Regulator of Vascular Aging